Health-economic aspects of cystic fibrosis screening and therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293404" target="_blank" >RIV/00064203:_____/14:10293404 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/14:10293404
Result on the web
<a href="http://dx.doi.org/10.1183/1025448x.10010613" target="_blank" >http://dx.doi.org/10.1183/1025448x.10010613</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/1025448x.10010613" target="_blank" >10.1183/1025448x.10010613</a>

Result language
angličtina
Original language name
Health-economic aspects of cystic fibrosis screening and therapy
Original language description
There is an increasing need to manage cost-effectiveness issues of novel or relatively expensive technologies that are currently in use or being proposed for the treatment of cystic fibrosis (CF) (e.g. cystic fibrosis transmembrane conductance regulator(CFTR) modulation therapy). Health-economic evaluations of rising pharmacotherapeutic costs, as the major driver of overall cost, have to be part of the cost analysis of chronic and progressive (rare) diseases like CF that may require lifelong therapy. Total costs include not only direct healthcare costs but also the cost of lost productivity by both patients and family caregivers. When considering the results of cost-effectiveness analysis of new technologies associated with the management of CF, it isunreasonable to expect that the incremental cost-effectiveness ratio to be less than the generally applied thresholds (willingness to pay) for other common diseases. Therefore, when assessing CF and other rare diseases, such analyses sho
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)